Official source · cited records
U.S. Food and Drug Administration
82 public records from U.S. Food and Drug Administration that PeptideScanner profiles or records cite, newest check first. Inclusion is not a source rating, endorsement, or claim of comprehensive monitoring.
Page 1 of 1
Official source · 82 cited records
- Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗Source checked November 16, 2026
- Drugs@FDA: COPAXONE (glatiramer acetate), NDA 020622 · original approval December 20, 1996 ↗Source checked November 16, 2026
- Drugs@FDA: DALVANCE (dalbavancin hydrochloride), NDA 021883 · original approval May 23, 2014 ↗Source checked November 16, 2026
- Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗Source checked November 16, 2026
- Drugs@FDA: FOUNDAYO (orforglipron calcium), NDA 220934 · original approval April 1, 2026 ↗Source checked November 16, 2026
- Drugs@FDA: INCRELEX (mecasermin [rDNA origin]), application 021839 · original approval August 30, 2005 ↗Source checked November 16, 2026
- Drugs@FDA: KYPROLIS (carfilzomib), NDA 202714 · original approval July 20, 2012 ↗Source checked November 16, 2026
- Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗Source checked November 16, 2026
- Drugs@FDA: MYALEPT (metreleptin), application 125390 · original approval February 24, 2014 ↗Source checked November 16, 2026
- Drugs@FDA: NETSPOT (gallium dotatate Ga-68), NDA 208547 · original approval June 1, 2016 ↗Source checked November 16, 2026
- Drugs@FDA: OMONTYS (peginesatide acetate), NDA 202799 · original approval March 27, 2012 ↗Source checked November 16, 2026
- Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗Source checked November 16, 2026
- Lantus (insulin glargine) prescribing information, application 021081 supplements S-078 and S-079, revised June 2023 ↗Source checked November 16, 2026
- Meeting of the Pharmacy Compounding Advisory Committee (before the end of February 2027) · content current as of April 15, 2026 ↗Source checked November 16, 2026
- Mycapssa (octreotide) prescribing information, NDA 208232 supplement S-006, revised July 2024 ↗Source checked November 16, 2026
- Sandostatin LAR Depot (octreotide acetate) prescribing information, NDA 021008 supplement S-049, revised July 2024 ↗Source checked November 16, 2026
- December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗Source checked November 15, 2026
- Drugs@FDA: ANGIOMAX (bivalirudin), NDA 020873 · original approval December 15, 2000 ↗Source checked November 15, 2026
- Drugs@FDA: APHEXDA (motixafortide acetate), NDA 217159 · original approval September 8, 2023 ↗Source checked November 15, 2026
- Drugs@FDA: BEXLUTRY (lutetium Lu-177 dotatate), NDA 218525 · original approval September 14, 2026 ↗Source checked November 15, 2026
- Drugs@FDA: CETROTIDE (cetrorelix acetate), NDA 021197 · original approval August 11, 2000 ↗Source checked November 15, 2026
- Drugs@FDA: CHIRHOSTIM (secretin synthetic human), NDA 021256 · original approval April 9, 2004 ↗Source checked November 15, 2026
- Drugs@FDA: CUBICIN and CUBICIN RF (daptomycin), NDA 021572 · original approval September 12, 2003 ↗Source checked November 15, 2026
- Drugs@FDA: DAYBUE (trofinetide), NDA 217026 · original approval March 10, 2023 ↗Source checked November 15, 2026
- Drugs@FDA: DDAVP (desmopressin acetate), NDA 019955 · original approval September 6, 1995 ↗Source checked November 15, 2026
- Drugs@FDA: EMPAVELI (pegcetacoplan), NDA 215014 · original approval May 14, 2021 ↗Source checked November 15, 2026
- Drugs@FDA: FIRAZYR (icatibant acetate), NDA 022150 · original approval August 25, 2011 ↗Source checked November 15, 2026
- Drugs@FDA: FIRMAGON (degarelix acetate), NDA 022201 · original approval December 24, 2008 ↗Source checked November 15, 2026
- Drugs@FDA: FUZEON (enfuvirtide), NDA 021481 · original approval March 13, 2003 ↗Source checked November 15, 2026
- Drugs@FDA: Ganirelix acetate (Organon), NDA 021057 · original approval July 29, 1999 ↗Source checked November 15, 2026
- Drugs@FDA: GATTEX (teduglutide), NDA 203441 · original approval December 21, 2012 ↗Source checked November 15, 2026
- Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗Source checked November 15, 2026
- Drugs@FDA: INTEGRILIN (eptifibatide), NDA 020718 · original approval May 18, 1998 ↗Source checked November 15, 2026
- Drugs@FDA: KORSUVA (difelikefalin acetate), NDA 214916 · original approval August 23, 2021 ↗Source checked November 15, 2026
- Drugs@FDA: LUTATHERA (lutetium Lu-177 dotatate), NDA 208700 · original approval January 26, 2018 ↗Source checked November 15, 2026
- Drugs@FDA: MIACALCIN (calcitonin salmon), NDA 017808 · original approval July 3, 1986 ↗Source checked November 15, 2026
- Drugs@FDA: MIMRYLO (rusfertide acetate), NDA 220605 · original approval August 28, 2026 ↗Source checked November 15, 2026
- Drugs@FDA: NATRECOR (nesiritide), NDA 020920 · original approval August 10, 2001 ↗Source checked November 15, 2026
- Drugs@FDA: PARSABIV (etelcalcetide), NDA 208325 · original approval February 7, 2017 ↗Source checked November 15, 2026
- Drugs@FDA: PITOCIN (oxytocin), NDA 018261 · original approval November 19, 1980 ↗Source checked November 15, 2026
- Drugs@FDA: SIGNIFOR (pasireotide diaspartate), NDA 200677 · original approval December 14, 2012 ↗Source checked November 15, 2026
- Drugs@FDA: SUPPRELIN LA (histrelin acetate), NDA 022058 · original approval May 3, 2007 ↗Source checked November 15, 2026
- Drugs@FDA: SYFOVRE (pegcetacoplan), NDA 217171 · original approval February 17, 2023 ↗Source checked November 15, 2026
- Drugs@FDA: SYNAREL (nafarelin acetate), NDA 019886 · original approval February 13, 1990 ↗Source checked November 15, 2026
- Drugs@FDA: TERLIVAZ (terlipressin acetate), NDA 022231 · original approval September 14, 2022 ↗Source checked November 15, 2026
- Drugs@FDA: TRELSTAR (triptorelin pamoate), NDA 020715 · original approval June 15, 2000 ↗Source checked November 15, 2026
- Drugs@FDA: VASOSTRICT (vasopressin), NDA 204485 · original approval April 17, 2014 ↗Source checked November 15, 2026
- Drugs@FDA: YORVIPATH (palopegteriparatide), NDA 216490 · original approval August 9, 2024 ↗Source checked November 15, 2026
- Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗Source checked November 15, 2026
- Drugs@FDA: ZILBRYSQ (zilucoplan sodium), NDA 216834 · original approval October 17, 2023 ↗Source checked November 15, 2026
- Drugs@FDA: ZOLADEX (goserelin acetate), NDA 019726 · original approval December 29, 1989 ↗Source checked November 15, 2026
- FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗Source checked November 15, 2026
- FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗Source checked November 15, 2026
- FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗Source checked November 15, 2026
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗Source checked November 15, 2026
- Certain bulk drug substances for use in compounding that may present significant safety risks ↗Source checked November 14, 2026
- FDA briefing document for BPC-157-related bulk drug substances ↗Source checked November 14, 2026
- FDA briefing document for epitalon ↗Source checked November 14, 2026
- FDA briefing document for KPV ↗Source checked November 14, 2026
- FDA briefing document for MOTS-c ↗Source checked November 14, 2026
- FDA briefing document for Semax ↗Source checked November 14, 2026
- FDA briefing document for TB-500 ↗Source checked November 14, 2026
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss · content current as of October 1, 2026 ↗Source checked November 14, 2026
- July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗Source checked November 14, 2026
- Langlara (insulin glargine-aldy): BLA 761412 approval letter, April 29, 2026 ↗Source checked November 14, 2026
- Mounjaro (tirzepatide): NDA 215866 supplements S-044 and S-045 approval letter, August 27, 2026 ↗Source checked November 14, 2026
- Vobrig (leuprolide acetate): NDA 213225 approval letter, August 26, 2026 ↗Source checked November 14, 2026
- Vyleesi (bremelanotide): NDA 210557 supplement S-005 approval letter, October 22, 2026 ↗Source checked November 14, 2026
- Zepbound (tirzepatide): NDA 217806 supplement S-041 corrected approval letter, effective August 26, 2026 ↗Source checked November 14, 2026
- ADLYXIN, revised November 2024: U.S. prescribing information ↗Source checked September 15, 2026
- FDA evaluation of five CJC-1295-related bulk substances, November 15, 2024 ↗Source checked September 15, 2026
- FDA evaluation of ipamorelin-related bulk substances, August 19, 2024 ↗Source checked September 15, 2026
- Forzinity (elamipretide): NDA 215244 accelerated approval letter, September 19, 2025 ↗Source checked September 15, 2026
- FORZINITY, revised September 2025: U.S. prescribing information ↗Source checked September 15, 2026
- FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗Source checked July 29, 2026
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗Source checked July 29, 2026
- FDA proposes to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list ↗Source checked July 29, 2026
- FDA requests removal of suicidal behavior and ideation warning from certain GLP-1 RA labels ↗Source checked July 29, 2026
- FDA warning letter to Gram Peptides ↗Source checked July 29, 2026
- 503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗Source checked July 22, 2026
- FDA approves higher-dose semaglutide ↗Source checked July 22, 2026
- FDA approves tirzepatide for chronic weight management ↗Source checked July 22, 2026